A new chemotherapy‐free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27289 ↗Kurz gefasst
Leserbrief in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Hailong Tang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Sulfonamides, Dexamethasone, Bridged Bicyclo Compounds, Heterocyclic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 6 Literaturangaben. Gefördert von: Translational Project of National Medical Center, Clinical New Technology Application Innovation Project of the Fourth Military Medical University, National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
- Department of Hematology, Weinan Central Hospital, Weinan, China.
ORCID-Profile: Hailong Tang, Shuangshuang Jia, Guangxun Gao
Förderung
- Translational Project of National Medical Center
- Clinical New Technology Application Innovation Project of the Fourth Military Medical University
- National Natural Science Foundation of China
- Health Scientific Research Innovation Ability Improvement Project of Shaanxi Province
- Social Development Key Project of Shaanxi Province
Zitieren
APA
Tang, H., Jia, W., Jia, S., Dong, R., Gao, S., Feng, J., Dong, H., Gu, H., Zhang, T., Yuan, R., Liu, X., Cheng, L., Zhou, S., & Gao, G. (2024). A new chemotherapy‐free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study. American Journal of Hematology. https://doi.org/10.1002/ajh.27289
Vancouver
Tang H, Jia W, Jia S, Dong R, Gao S, Feng J, et al. A new chemotherapy‐free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study. American Journal of Hematology. 2024. doi:10.1002/ajh.27289
BibTeX
@article{Tang2024,
author = {Tang, Hailong and Jia, Weijing and Jia, Shuangshuang and Dong, Runan and Gao, Shan and Feng, Juan and Dong, Hongjuan and Gu, Hongtao and Zhang, Tao and Yuan, Ruifeng and Liu, Xiangxiang and Cheng, Lu and Zhou, Shuya and Gao, Guangxun},
title = {A new chemotherapy‐free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27289}
}
EUVIMED